Eisai To Sell Value-Added Generics

BMI's newest long-term core view is that the generic drug industry will stratify into the following sub-sectors: unbranded/commodity generics; branded generics; value-added generics; and hard-to-manufacture generics, such as biosimilars.

To read the full article, please choose one of the following options: